Alvaro Moreira

Dr. Alvaro Moreira

The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Immunity
Verified
Journal Article
Closed access
NVNicolas Vabret
Nicolas Vabret
GBGraham Britton
Graham Britton
CGConor Gruber
Conor Gruber
SHSamarth Hegde
Samarth Hegde
JKJoel Kim
Joel Kim
ULUri Laserson
Uri Laserson

1 January 2019 in European Journal of Cancer
Verified
Journal Article
Closed access
AMAlvaro Moreira
Alvaro Moreira
CLCarmen Loquai
Carmen Loquai
CPClaudia Pföhler
Claudia Pföhler
KKKatharina C. Kähler
Katharina C. Kähler
SKSamuel Knauss
Samuel Knauss
LHLucie Heinzerling
Lucie Heinzerling

27 January 2017 in Immunotherapy
Verified
Journal Article
Closed access
AMAlvaro Moreira
Alvaro Moreira
WLWaltraud Leisgang
Waltraud Leisgang
GSGerold Schuler
Gerold Schuler
LHLucie Heinzerling
Lucie Heinzerling
Aim: The prognostic role of eosinophils in cancer has been controversial. Some entities such as gastrointestinal cancers show a better survival, while others such as Hodgkin's lymphoma a worse survival in patients with eosinophilia. Patients who exhibited an increase in eosinophils upon therapy with ipilimumab or pembrolizumab were shown to survive longer. We wanted to investigate whether eosinophilia is a prognostic marker in metastatic melanoma. Methods: In total, 173 patients with metastatic melanoma from our data base (median age 60 years; n = 86 with immunotherapy, n = 87 without immunotherapy) were analyzed for eosinophil counts and survival over the course of 12 years. Eosinophilic count was detected by peripheral blood smear. The ethical committee had approved this retrospective study. Results: Melanoma patients with eosinophilia at any point in their course of disease show a trend toward longer survival independently of their therapy. There is a statistically significant difference for the patien...

3 May 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
TETomohiro Enokida
Tomohiro Enokida
AMAlvaro Moreira
Alvaro Moreira
NBNina Bhardwaj
Nina Bhardwaj
The immunoprevention of cancer and cancer recurrence is an important area of concern for the scientific community and society as a whole. Researchers have been working for decades to develop vaccines with the potential to alleviate these health care and economic burdens. So far, vaccines have made more progress in preventing cancer than in eliminating already established cancer. In particular, vaccines targeting oncogenic viruses, such as the human papillomavirus and the hepatitis B virus, are exceptional examples of successful prevention of virus-associated cancers, such as cervical cancer and hepatocellular carcinoma. Cancer-preventive vaccines targeting nonviral antigens, such as tumor-associated antigens and neoantigens, are also being extensively tested. Here, we review the currently approved preventive cancer vaccines; discuss the challenges in this field by covering ongoing preclinical and clinical human trials in various cancers; and address various issues related to maximizing cancer vaccine benefit.

4 December 2018 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
AMAlvaro Moreira
Alvaro Moreira
SGStefanie Gross
Stefanie Gross
MKMichael Constantin Kirchberger
Michael Constantin Kirchberger
MEMichael Erdmann
Michael Erdmann
GSGerold Schuler
Gerold Schuler
LHLucie Heinzerling
Lucie Heinzerling

9 January 2021 in Cancers
Verified
Journal Article
Open access
PDF file
AMAlvaro Moreira
Alvaro Moreira
LHLucie Heinzerling
Lucie Heinzerling
NBNina Bhardwaj
Nina Bhardwaj
PFPhilip Friedlander
Philip Friedlander
Groundbreaking research in immunology and cancer biology in the last few decades has led to the discovery and development of novel therapeutics, such as immune checkpoint inhibitors and targeted therapies, which have revolutionized the clinical care of patients with metastatic melanoma. Updated data from the largest clinical trials continue to support the use of these treatment modalities, both in the metastatic and in adjuvant settings, with studies showing the predicted plateau effect on survival curves. However, with growing evidence that neoadjuvant therapy is also associated with high rates of recurrence-free survival, the question about whether patients should receive adjuvant or neoadjuvant treatment raises new questions about therapeutic options. Finally, management after resistance and intervention with novel immunotherapies are newer challenges, particularly in the field of non-cutaneous melanoma.